Ignite Creation Date:
2024-05-06 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 12:46 PM
Study NCT ID:
NCT03535740
Status:
COMPLETED
Last Update Posted:
2023-08-25
First Post:
2018-05-09
Brief Title:
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive ALK Advanced Non-Small-Cell Lung Cancer NSCLC Progressed on Alectinib or Ceritinib
Sponsor:
Organization:
Takeda
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
103
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: